US38870X1046 - Common Stock
GRAPHITE BIO INC
NASDAQ:GRPH (3/21/2024, 8:00:01 PM)
After market: 3.22 +0.04 (+1.26%)3.18
-0.09 (-2.75%)
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
GRAPHITE BIO INC
611 Gateway Blvd, Suite 120
South San Francisco CALIFORNIA
P: 16504840886
CEO: Josh Lehrer
Employees: 120
Website: https://graphitebio.com/
Pre-market stock movers are a great way to start the week as we check out all of the biggest trades happening on Monday morning!
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Here you can normally see the latest stock twits on GRPH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: